The Extent of Honeycombing on Computed Tomography Cannot Predict the Treatment Outcome of Patients with Acute Exacerbations of Interstitial Lung Disease

Table 3

Clinical comparison of patients with and without honeycombing.

Characteristics	With honeycombing (N = 52)	Without honeycombing (N = 43)	Total patients (N = 95)	values with vs. without honeycombing
Age, y	78 (73–82)	74 (66–79)	75 (71–80)	0.013
Male sex	35 (67)	33 (76)	68 (72)	0.310
CCIS	6 (5–7)	4.5 (3–8.8)	6 (4–7)	0.411
From ILDs diagnosis to AE treatment, days	1390 (739–2482)	590 (56–1870)	1103 (229–2103)	0.011
From symptom onset to treatment, days	6 (2.8–16.3)	6 (2.3–14)	6 (3–15)	0.128
Physiological parameter
P/F ratio	266 (202–307)	271 (180–316)	268 (188–308)	0.686
Biomarkers
LDH (IU/L)	279 (248–340)	290 (210–415)	282 (237–404)	0.173
SP-D (ng/mL)	279 (154–507)	194 (110–366)	233 (139–407)	0.080
KL-6 (U/mL)	1058 (768–1910)	572(310–1202)	897 (563–1553)	0.008
Treatment
PSL before pulse	12 (23)	9 (21)	21 (22)	0.802
PSL pulse	52 (100)	43 (100)	95 (100)	1.000
PSL after pulse	43 (84)	34 (79)	77 (82)	0.511
Macrolide	6 (12)	14 (33)	20 (21)	0.012
Anticoagulant	9 (17)	9 (21)	18 (19)	0.652
Outcome
3-month mortality	14 (27)	9 (21)	23 (24)	0.497